STATUS OF ORPHAN DRUGS AND REIMBURSEMENT RECOMMENDATIONS AND DECISIONS IN ANALYSED EUROPEAN COUNTRIES

被引：0
|
作者：
Kawalec, P. [1 ]
Malinowski, K. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1450
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY133
引用
收藏
页码：A598 / A599
页数：2
相关论文
共 50 条
  • [31] REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
    Cheng, C. Y.
    Chan, H. W.
    Fang, C. H.
    VALUE IN HEALTH, 2019, 22 : S856 - S856
  • [32] THE "WEIGHT" OF ORPHAN DRUGS IN THE EUROPEAN PHARMACEUTICAL POLICY. A FOCUS ON THE EXPENDITURE AND THE UTILIZATION OF ORPHAN DRUGS IN FIVE EUROPEAN UNION COUNTRIES
    Muscolo, L. A. A.
    Deriu, D.
    Sammarco, A.
    Siviero, P. D.
    Pani, L.
    VALUE IN HEALTH, 2012, 15 (04) : A20 - A20
  • [33] REIMBURSEMENT STATUS OF EUROPEAN MEDICINES AGENCY AUTHORISED DRUGS IN SPAIN
    Carmo, M.
    Aguilar, L.
    Pinel, M.
    Perulero, N.
    Rebollo, P.
    Merino-Montero, S.
    Callejo-Velasco, D.
    VALUE IN HEALTH, 2022, 25 (12) : S255 - S255
  • [34] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [35] REIMBURSEMENT STATUS OF CENTRALLY AUTHORIZED DRUGS IN SPAIN PER THERAPEUTIC AREA AND ORPHAN DESIGNATION
    Carmo, M.
    Aguilar Sugranes, L.
    Olivella, A.
    Aires, A.
    Lloret Avella, M.
    Pinel, M.
    Callejo, D.
    VALUE IN HEALTH, 2023, 26 (12) : S289 - S289
  • [36] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [37] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [38] How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
    Blonda, Alessandra
    Denier, Yvonne
    Huys, Isabelle
    Kawalec, Pawel
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] ELIGIBILITY OF ORPHAN DRUGS FOR PREFERENTIAL REIMBURSEMENT IN EGYPT
    Fasseeh, A. N.
    Elezbawy, B.
    Korra, N.
    Roushdy, M.
    Seyam, A.
    Hayek, N.
    Rahman, Abdel N.
    Abdelhamid, S.
    Fasseeh, N.
    Saad, A. S.
    Elagamy, A.
    Mahmoud, A.
    Sedrak, A. S.
    Elshazly, K.
    Eldebeiky, M.
    Talaat, M.
    Maher, N.
    Abdelaziz, R.
    Refaat, R.
    Akeel, S.
    Adel, R.
    Khalil, S.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S265 - S265
  • [40] Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
    Kleijnen, S.
    Lipska, I.
    Alves, T. Leonardo
    Meijboom, K.
    Elsada, A.
    Vervoelgyi, V.
    d'Andon, A.
    Timoney, A.
    Leufkens, H. G.
    De Boer, A.
    Goettsch, W. G.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1768 - 1775
12345